CAMBRIDGE, Massachusetts, and SOUTH SAN FRANCISCO, California, USA –
Ultivue, Inc. and Fluidigm Corporation (Nasdaq: FLDM) today announced a co-marketing agreement under which the companies will provide customers with a comprehensive portfolio of workflow solutions for biomarker research and drug development.
Ultivue, a leading precision medicine solutions provider driving the discovery and validation of tissue biomarkers, is developing unique assays for use in multiplex immunofluorescence imaging and analysis. The proprietary InSituPlex®-Technology is designed for the quick and comprehensive examination of biologically relevant markers in connection with the HE staining of the same slide with valuable tissue samples.
Fluidigm is a leader in high parameter imaging for clinical translational research and clinical testing. IMC ™ (Imaging Mass Cytometry ™) technology was developed for highly multiplexed, targeted examination of tissue sections for 40 or more protein markers in one scan, with distinct, non-overlapping signals from element-labeled antibodies being captured simultaneously for each submicron pixel.
The cooperation creates a comprehensive range of services for researchers on clinical and translational projects. The InSituPlex technology is, for example, very well suited for identifying relevant regions that require detailed profiling with IMC ™ at a later date. The availability of both technologies can improve the efficiency of drug discovery programs and enable patient stratification in translational research to select cases for further investigation.
“Imaging Mass Cytometry has become an integral part of the clinical translational research and clinical testing markets,” said Chris Linthwaite, President and CEO, Fluidigm. “Through Fluidigm Therapeutic Insights Services, we will give our customers access to our technology and that of Ultivue, providing optimal imaging solutions for biomarker research and drug development.”
“Ultivue’s innovative strength enables it to deliver unique biological insights to its customers,” said Mark Rees, vice president of business development, Ultivue. “Our InSituPlex®-Technology supports high-quality profiling of the tissue and expands the spectrum of information that can be obtained from a single section and complements the highly parametric capabilities of Imaging Mass Cytometry. We are convinced that this joint offer with Fluidigm will provide researchers with a smooth workflow that enables significantly more efficient processes in biomarker discovery and drug development. ”
About Fluidigm
Fluidigm Corporation (Nasdaq: FLDM) specializes in the most urgent needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidic technologies, we develop, produce and market multi-omics solutions to gain meaningful insights into health and disease, to identify biomarkers as a basis for decision-making and to accelerate the development of more effective therapies. Our customers include leading academic, government, pharmaceutical, biotechnology, and clinical laboratories, and plant and animal research centers around the world. Together with our customers, we strive to improve the quality of life for everyone.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and / or registered trademarks of Fluidigm Corporation in the United States and / or other countries. All other trademarks are the property of their respective owners. For research use only. Not approved for use in diagnostic procedures. More information is available at fluidigm.com.
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplexed biomarker assays for tissue phenotyping and digital pathology. The proprietary InSituPlex® -Technology allows advanced research and examination of tissue samples in the field of precision medicine. These highly customizable solutions, as well as the scientific advisory approach, strengthen and accelerate biomarker discovery and drug development programs. More information is available at ultivue.com.
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. You should therefore compare the translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20210805006189/de/
Quelle: Business Wire
– .
